Peripheral and central inhibitors of catechol-O-methyl transferase: Effects on liver and brain COMT activity and L-DOPA metabolism

Journal of Neural Transmission

Volumn 104, Issue 1, 1997, Pages 77-87

  Brannan, T ^a   Prikhojan, A ^a   Yahr, M D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cerebral microdialysis; COMT; Dinitrocatechol; Dopamine; Entacapone; L DOPA; Parkinson's disease

Indexed keywords

BRAIN ENZYME; CARBIDOPA; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; DINITROCATECHOL; DOPAMINE; ENTACAPONE; HOMOVANILLIC ACID; LEVODOPA; LIVER ENZYME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN METABOLISM; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DRUG EFFECT; DRUG METABOLISM; DRUG PENETRATION; ENZYME ACTIVITY; ENZYME INHIBITION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BRAIN; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; DOPAMINE; HOMOVANILLIC ACID; LEVODOPA; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0031016506     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01271296     Document Type: Article

References (21)

1. Brannan T, Martínez-Tica J, Yahr MD (1991) Effect of dietary protein on striatal dopamine formation following L-DOPA administration: an in vivo study. Neuropharmacology 30: 1125-1127
2. Brannan T, Martínez-Tica J, Yahr MD (1992) Catechol-O-methyltransferase inhibition increases striatal L-DOPA and dopamine: an in vivo study in rats. Neurology 42: 683-685
3. Brannan T, Martínez-Tica J, Yahr MD (1992) Changes in body temperature markedly affect striatal dopamine release and metabolism: an in vivo study. J Neural Transm [Gen Sect] 89: 193-196
4. Kaakkola S, Wurtman RJ (1992) Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study. Brain Res 587: 241-249
5. Kaakkola S, Wurtman RJ (1993) Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum. J Neurochem 60(1): 137-144
6. Kaakkola S, Gordin A, Männisto PT (1994) General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen Pharmac 25: 813-824
7. Kaakkola S, Teravainen H, Ahtila S, Rita H, Gordin A (1994) Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 44(1): 77-8
8. Kaakkola S, Teravainen H, Ahtila S, Karlsson M, Naukkarinen T, Rita H, Gordin A (1995) Entacapone in combination with standrd or controlled-release levodopa/ carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease. Eur J Neurol 2: 1-7
9. Maj J, Rogóz G, Skuza G, Sowínska H, Superata J (1990) Behavioral and neurochemical effects of Ro 40-7592, a new COMT inhititor with a potential therapeutic activity in Parkinson's disease. J Neural Transm [P-D Sect] 2: 101-112
10. Männistö PT, Toumainen P, Tuominen RK (1992) Different in vivo properties of three new inhibitors of catechol-O-methyltransferase. Br J Pharmacol 105: 569-574
11. Mena MA, Muradas V, Bazan E, Reintz J, de Yebenez JG (1987) Pharmacokinetics of L-DOPA in patients with Parkinson's disease. In: Yahr MD, Bergmann KJ (eds) Parkinson's disease. Raven Press, New York, pp 481-492 (Adv Neurol 45)
12. Merello M, Lees AJ, Webster R, Bovingdon M, Gordin A (1994) Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 57(2): 186-9
13. Nissinen E, Linden IB, Schultz E, Kaakkola S, Männistö PT, Pohto P (1988) Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat. Eur J Pharmacol 153: 263-269
14. Nissinen E, Linden IB, Schultz E, Pohto P (1992) Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol 346(3): 262-6
15. Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren K, Carter JH, Gancher ST. Hammerstad JP, Gordin A (1994) Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44(5): 913-9
16. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN (1983) Catechol-O-methyl transferase inhibitor tolcapone prolongs levodopa/ carbidopa action in parkinson patients. Neurology 43: 2685-2688
17. Schultz E, Nissinen E, Kaakkola S (1989) Determination of catechol-O-methyltransferase activity in erythrocytes by high performance liquid chromatography with electrochemical detection. Biomed Chromatogr 3: 64-67
18. Shoup RE, Davis GC, Kissinger PT (1980) Determination of catechol-O-methyltransferase activity in various tissues by liquid chromatography. Anal Chem 52: 483-487
19. Törnwall M, Tuomainen P, Männistö PT (1992) Neurochemical and psychomotor interadctions of new selective COMT inhibitors with clorgyline and nomifensene in levodopa-treated rats and mice. Arch Int Pharmacodyn 320: 5-20
20. Törnwall M, Tuomainen P, Männistö PT (1993) Modulation of rat brain endogenous dopamine metabolism by new inhibitors of catechol-O-methyltransferase. Eur J Pharmacol 239: 39-45
21. Törnwall M, Kaakkola S, Tuomainen P, Kask A, Männistö PT (1994) Comparison of two new inhibitors of catechol-O-methylation on striatal dopamine metabolism: a microdialysis study. Br J Pharmacol 112: 13-18